A
Akos F. Pap
Researcher at Bayer
Publications - 35
Citations - 6554
Akos F. Pap is an academic researcher from Bayer. The author has contributed to research in topics: Rivaroxaban & Population. The author has an hindex of 18, co-authored 33 publications receiving 5571 citations. Previous affiliations of Akos F. Pap include Bayer Corporation & Bayer HealthCare Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
John P. Neoptolemos,Deborah D. Stocken,Helmut Friess,Claudio Bassi,Janet A. Dunn,Helen Hickey,Hans G. Beger,Laureano Fernández-Cruz,Christos Dervenis,François Lacaine,Massimo Falconi,Paolo Pederzoli,Akos F. Pap,David Spooner,David J. Kerr,Markus W. Büchler +15 more
TL;DR: Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.
Journal ArticleDOI
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
Ajay K. Kakkar,Benjamin Brenner,Ola E. Dahl,Bengt I. Eriksson,Patrick Mouret,James Muntz,Andrea G. Soglian,Akos F. Pap,Frank Misselwitz,Sylvia Haas +9 more
TL;DR: Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty.
Journal ArticleDOI
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
John P. Neoptolemos,Janet A. Dunn,Deborah D. Stocken,J. Almond,Karl-Heinrich Link,H. G. Beger,Claudio Bassi,Massimo Falconi,Paolo Pederzoli,Christos Dervenis,Laureano Fernández-Cruz,François Lacaine,Akos F. Pap,David Spooner,David J. Kerr,Helmut Friess,Markus W. Büchler +16 more
TL;DR: This study showed no survival benefit for chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy, justifying further randomised controlled trials of adjUvant chemotherapy in pancreatic cancer.
Journal ArticleDOI
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Jeffrey I. Weitz,Anthonie W. A. Lensing,Martin H. Prins,Rupert Bauersachs,Jan Beyer-Westendorf,Henri Bounameaux,Timothy A. Brighton,Alexander T. Cohen,Bruce L. Davidson,Hervé Decousus,Maria Cecilia S. Freitas,Gerlind Holberg,Ajay K. Kakkar,Lloyd Haskell,Bonno van Bellen,Akos F. Pap,Scott D. Berkowitz,Peter Verhamme,Philip S. Wells,Paolo Prandoni +19 more
TL;DR: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates.
Journal ArticleDOI
Rivaroxaban in Peripheral Artery Disease after Revascularization
Marc P. Bonaca,Rupert Bauersachs,Sonia S. Anand,E Sebastian Debus,Mark R. Nehler,Manesh R. Patel,Fabrizio Fanelli,Warren H. Capell,Lihong Diao,Nicole Jaeger,Connie N. Hess,Akos F. Pap,John Kittelson,Ivan Gudz,Lajos Mátyás,Dainis Krievins,Rafael Diaz,Marianne Brodmann,Eva Muehlhofer,Lloyd Haskell,Scott D. Berkowitz,William R. Hiatt +21 more
TL;DR: In patients with peripheral artery disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone.